Abstract

To describe real-world treatment duration in anaplastic lymphoma kinase positive (ALK+) NSCLC patients receiving brigatinib. This retrospective study used United States (US) specialty pharmacy data to identify all patients receiving brigatinib between May 2017 and November 2018. During this data collection period, brigatinib was approved in the US for patients with crizotinib-resistant metastatic ALK+ NSCLC. The study outcome was time to discontinuation, which was evaluated using Kaplan-Meier survival analysis. Dosing information obtained through prescribers’ instructions was described. 455 patients received brigatinib through the specialty pharmacy database during the study period. Of these, 313 patients (68.8%) received 90 mg/d for 7 days and escalated to 180 mg/d; 89 patients (19.6%) only received 180 mg/d and 24 patients (5.3%) only received 90 mg/d during study follow-up; and 29 (6.4%) patients received other dose combinations including 60 mg, 90 mg, 120 mg, 150 mg, 180 mg, and 240 mg qd. These data may not reflect initiation of drug for all patients, as patients may have received drug prior to specialty pharmacy. Overall, 374 patients (82.2%) received brigatinib 180 mg/d as their most recent dose. The median time to discontinuation was 16.4 months (95% CI: 11.0, NE). Kaplan-Meier estimates of continued use of brigatinib for specialty pharmacy patients at months 1 through 6 and at 12 months of the study period were 91.5%, 86.6%, 80.8%, 75.7%, 69.8%, 67.9% and 54.9%. In the real world, despite a mixed patient population across all treatment lines, estimates for continued brigatinib use remained high over time. In the absence of reported clinical outcomes in the real-world setting, time to discontinuation may be used as a proxy for the tolerability and effectiveness of brigatinib.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.